Last Posted: Mar 05, 2020
- Prediction Rule for Nonresponse to Clopidogrel: ABCD-GENE Score
ACC, March 3, 2020 - International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing.
Pereira Naveen L et al. Pharmacogenetics and genomics 2019 29(4) 76-83 - Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Limdi Nita A et al. The pharmacogenomics journal 2020 Feb - Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Pragmatic Randomized Clinical Trial.
Tuteja Sony et al. Circulation. Genomic and precision medicine 2020 Jan - Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention.
Hart M Ragan et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2019 Nov 22(11) 1231-1239 - Clopidogrel Pharmacogenetics - Why the Wait?
Roden Dan M et al. The New England journal of medicine 2019 10 (17) 1677-1678 - A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI.
Claassens Daniel M F et al. The New England journal of medicine 2019 Oct (17) 1621-1631 - Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.
Zhu Ye et al. Genetics in medicine : official journal of the American College of Medical Genetics 2019 Oct - Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine.
Zaiou M et al. Clinical genetics 2017 91(3) 355-370 - Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients.
Lewis Joshua P et al. European heart journal. Cardiovascular pharmacotherapy 2019 Sep
.png)
No hay comentarios:
Publicar un comentario